Results 41 to 50 of about 146,743 (148)

Elotuzumab in combination with pomalidomide, bortezomib, and dexamethasone in relapsed and refractory multiple myeloma

Blood Advances
: Elotuzumab is a monoclonal antibody targeting signaling lymphocyte activation molecule F7 on plasma and natural killer cells, which enhances the activity of lenalidomide, pomalidomide, and bortezomib in multiple myeloma (MM). The OPTIMISMM study showed
Andrew J. Yee, Jacob P. Laubach, Erica L. Campagnaro, Brea C. Lipe, Omar Nadeem, Robb S. Friedman, Craig E. Cole, Elizabeth K. O’Donnell, Giada Bianchi, Andrew R. Branagan, Robert L. Schlossman, Samantha J. Shapiro, Cynthia C. Harrington, Jill N. Burke, Marilyn T. Gammon, Kathleen J. Lively, Cassandra A. Reimonn, Danielle X. Andrade, Robert Redd, Jens G. Lohr, Kenneth C. Anderson, Paul G. Richardson, Noopur S. Raje   +22 more
doaj   +1 more source

Elranatamab: A novel B-cell maturation T-cell engager

Human Vaccines & Immunotherapeutics
B-cell maturation antigen (BCMA) is a highly expressed transmembrane receptor on malignant plasma cells, mediating cell survival. These characteristics make it an attractive target for novel cellular and immunotherapies.
Shahrier Hossain, Giada Bianchi
doaj   +1 more source

Genomic patterns of progression in smoldering multiple myeloma

Nature Communications, 2018
Smoldering MM (SMM) is a premalignant stage of multiple myeloma (MM). Here the authors perform whole genome sequencing of unique paired samples of SMM progressing to MM, and show that the genomic landscape at the SMM stage is very similar to MM, but ...
Niccolò Bolli, Francesco Maura, Stephane Minvielle, Dominik Gloznik, Raphael Szalat, Anthony Fullam, Inigo Martincorena, Kevin J. Dawson, Mehmet Kemal Samur, Jorge Zamora, Patrick Tarpey, Helen Davies, Mariateresa Fulciniti, Masood A. Shammas, Yu Tzu Tai, Florence Magrangeas, Philippe Moreau, Paolo Corradini, Kenneth Anderson, Ludmil Alexandrov, David C. Wedge, Herve Avet-Loiseau, Peter Campbell, Nikhil Munshi   +23 more
doaj   +1 more source

Non-overlapping Control of Transcriptome by Promoter- and Super-Enhancer-Associated Dependencies in Multiple Myeloma

Cell Reports, 2018
Summary: The relationship between promoter proximal transcription factor-associated gene expression and super-enhancer-driven transcriptional programs are not well defined.
Mariateresa Fulciniti, Charles Y. Lin, Mehmet K. Samur, Michael A. Lopez, Irtisha Singh, Matthew A. Lawlor, Raphael E. Szalat, Christopher J. Ott, Herve’ Avet-Loiseau, Kenneth C. Anderson, Richard A. Young, James E. Bradner, Nikhil C. Munshi   +12 more
doaj   +1 more source

Unlocking the therapeutic potential of selective CDK7 and BRD4 Inhibition against multiple myeloma cell growth

Haematologica
Multiple myeloma (MM) is a plasma cell malignancy considered incurable despite the recent therapeutic advances. Effective targeted therapies are therefore needed.
Yao Yao, Shuhui Deng, Jessica Fong Ng, Mei Yuan, Chandraditya Chakraborty, Vera JoyWeiler, Nikhil Munshi, Mariateresa Fulciniti   +7 more
doaj   +1 more source

Autologous peripheral blood stem cell transplantation as front-line therapy for myeloma with double-hit and triple-hit in a real-world study

Chinese Medical Journal, 2021
Guang-Zhong Yang, Guo-Rong Wang, Yan-Chen Li, Yin Wu, Wen Gao, Wen-Ming Chen, Peng Lyu   +6 more
doaj   +1 more source

Real-World Data of Light Chain (AL) Amyloidosis: Prognostic Indices and Treatment Patterns

Biomedicines
Background: Limited real-world data (RWD) may provide important information regarding diagnostic and treatment patterns in patients (pts) with AL Amyloidosis. The aim was to analyze the characteristics, treatment approach and clinical outcome of patients
Marko Mitrovic, Aleksandra Sretenovic, Natalija Kecman, Nikola Vukosavljevic, Maja Perunicic Jovanovic, Dragana Sobic Saranovic, Ruzica Maksimovic, Zoran Bukumiric, Danijela Lekovic, Arsen Ristic, Milena Todorovic Balint, Jelena Bila   +11 more
doaj   +1 more source

Combining antigen-specific T cells with T-cell engager therapy induces a molecular signature that favors T-cell fitness

Blood Immunology & Cellular Therapy
: Both adoptive cellular therapy with tumor antigen–specific T cells and redirection of endogenous T cells with bispecific tumor-specific T-cell engaging antibodies rely on CD8+ T cell effector function. The two approaches use complementary mechanisms of
Manpreet Bariana, Sidharth Anand, Mark Batistick, Elena Cassella, Shaina A. Anuncio, Ariel Aptekmann, David S. Siegel, Mathias Oelke, Sojung Kim, Ruipeng Wang, Jack A. Ragheb, Johannes L. Zakrzewski   +11 more
doaj   +1 more source

Author Correction: The biological significance of histone modifiers in multiple myeloma: clinical applications

Blood Cancer Journal, 2021
Hiroto Ohguchi, Teru Hideshima, Kenneth C. Anderson   +2 more
doaj   +1 more source

Role of minimal residual disease assessment in multiple myeloma

Haematologica
Multiple myeloma (MM) is a hematologic malignancy characterized by clonal proliferation of plasma cells. MM is a heterogeneous disease, featured by various molecular subtypes with different outcomes. With the advent of very efficient therapies including
Raphael Szalat, Kenneth Anderson, Nikhil Munshi   +2 more
doaj   +1 more source